Last update July 10, 2017

Tizanidine Hydrochloride

High Risk

Poorly safe. Evaluate carefully. Use safer alternative or interrupt breastfeeding 3 to 7 T ½ (elimination half-lives). Read the Comment.

Centrally acting muscle relaxant.

Since the last update we have not found published data on its excretion in breast milk.

Its pharmacokinetic data: low molecular weight, high liposolubility (Acorda 2006), makes it probable that it could pass to milk in potentially significant quantities.

During breastfeeding, it seems prudent to avoid it (Hutchinson 2013) or to use it very sporadically and limited to sufficient minimum doses, monitoring for possible sedation of the infant, especially during the first 3 months of life.


We do not have alternatives for Tizanidine Hydrochloride.

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Tizanidine Hydrochloride in other languages or writings:


Tizanidine Hydrochloride belongs to this group or family:


Main tradenames from several countries containing Tizanidine Hydrochloride in its composition:


Variable Value Unit
Oral Bioavail. 40 %
Molecular weight 290 daltons
Protein Binding 30 %
VD 2.6 l/Kg
Tmax 1 hours
2 - 4 hours


  1. Hutchinson S, Marmura MJ, Calhoun A, Lucas S, Silberstein S, Peterlin BL. Use of common migraine treatments in breast-feeding women: a summary of recommendations. Headache. 2013 Abstract Full text (link to original source) Full text (in our servers)
  2. Mathias CJ, Luckitt J, Desai P, Baker H, el Masri W, Frankel HL. Pharmacodynamics and pharmacokinetics of the oral antispastic agent tizanidine in patients with spinal cord injury. J Rehabil Res Dev. 1989 Abstract

Total visits


Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at

e-lactancia is a resource recommended by El Parto Es Nuestro of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM